Mesenchymal cell proliferation and programmed cell death: Key players in fibrogenesis and new targets for therapeutic intervention

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 300, Issue 5, 2011, Pages

  Luna, Jeroni ^a   Masamunt, Maria Carme ^a   Lawrance, Ian Craig ^b   Sans, Miquel ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Crohn's disease; Inflammatory bowel disease

Indexed keywords

ANTIFIBROTIC AGENT; ANTIINFLAMMATORY AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

APOPTOSIS; CELL PROLIFERATION; CROHN DISEASE; ENTERITIS; FIBROGENESIS; HOMEOSTASIS; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOPATHOGENESIS; INTESTINAL FIBROSIS; MESENCHYME CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; APOPTOSIS; CELL PROLIFERATION; CROHN DISEASE; FIBROSIS; HUMANS; INFLAMMATORY BOWEL DISEASES; MESENCHYMAL STEM CELLS;

EID: 79955562519     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00504.2010     Document Type: Review

References (87)

1. Abreu MT, Taylor KD, Lin YC, Hang T, Gaiennie J, Landers CJ, Vasiliauskas EA, Kam LY, Rojany M, Papadakis KA, Rotter JI, Targan SR, Yang H. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology 123: 679-688, 2002.
2. Ahrenstedt O, Hallgren R, Knutson L. Jejunal release of prostaglandin E2 in Crohn's disease: relation to disease activity and first-degree relatives. J Gastroenterol Hepatol 9: 539-543, 1994.
3. Baker AJ, Mooney A, Hughes J, Lombardi D, Johnson RJ, Savill J. Mesangial cell apoptosis: the major mechanism for resolution of glomerular cellularity in experimental mesangial proliferative nephritis. J Clin Invest 94: 2105-2116, 1994.
4. Baskin L, Constantinescu S, Howard P, McAninch J, Ewalt D, Duckett J, Snyder H, Macarak E. Biochemical characterisation and quantitation of the collagenous components of urethral stricture tissue. J Urol 150: 642-647, 1993.
5. Bataller R, Ginès P, Nicolás J, Görbig M, Garcia-Ramallo E, Gasull X, Bosch J, Arroyo V, Rodés J. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 118: 1149-1156, 2000.
6. Birchmeier C, Birchmeier W, Gherardi E, Vande-Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4: 915-925, 2003.
7. Brand S, Hofbauer K, Dambacher J, Schnitzler F, Staudinger T, Pfennig S, Seiderer J, Tillack C, Konrad A, Göke B, Ochsenkühn T, Lohse P. Increased expression of the chemokine fractalkine in Crohn's disease and association of the fractalkine receptor T280M polymorphism with a fibrostenosing disease phenotype. Am J Gastroenterol 101: 99-106, 2006.
8. Buemi M, Allegra A, Marino D, Marino MT, Medici MA, De Pasquale G, Ruello A, Corica F, Frisina N. Does captopril have a direct proapoptotic effect? Nephron 81: 99-101, 1998.
9. Buzzelli G, Moscarella S, Giusti A, Duchini A, Marena C, Lampertico M. A pilot study on the liver protective effect of silybin-phosphatidylcholine complex (IdB1016) in chronic active hepatitis. Int J Clin Pharmacol Ther Toxicol 31: 456-460, 1993.
10. Cho JH. The NOD2 gene in Crohn's disease: implications for future research into the genetics and immunology of Crohn's disease. Inflamm Bowel Dis 7: 271-275, 2001.
11. Cooney R, Baker J, Brain O, Danis B, Pichulik T, Allan P, Ferguson DJ, Campbell BJ, Jewell D, Simmons A. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat Med 16: 90-97, 2010.
12. Corcoran ML, Stetler-Stevenson WG, Brown PD, Wahl LM. Interleukin 4 inhibition of prostaglandin E2 synthesis blocks interstitial collagenase and 92-kDa type IV collagenase/gelatinase production by human monocytes. J Biol Chem 267: 515-519, 1992.
13. Daly T, Weston W. Retinoid effects on fibroblast proliferation and collagen synthesis in vitro and on fibrotic disease in vivo. J Am Acad Dermatol 15: 900-902, 1986.
14. Davis BH, Rapp UR, Davidson NO. Retinoic acid and transforming growth factor beta differentially inhibit platelet-derived-growth-factorinduced Ito-cell activation. Biochem J 278: 43-47, 1991.
15. Faure S, Meyer L, Costagliola D, Vaneensberghe C, Genin E, Autran B, Delfraissy JF, McDermott DH, Murphy PM, Debré P, Théodorou I, Combadière C. Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1. Science 287: 2275-2277, 2000.
16. Feagan BG, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, Greenberg GR, Koval J, Wong CJ, Hopkins M, Hanauer SB, McDonald JW. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 342: 1627-1632, 2000.
17. Feghali C, Bost K, Boulware D, Levy L. Mechanisms of pathogenesis in scleroderma. I. Overproduction of interleukin 6 by fibroblasts cultured from affected skin sites of patients with scleroderma. J Rheumatol 19: 1207-1211, 1992.
18. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 275: 2247-2250, 2000.
19. Graham M, Drucker D, Perr H, Diegelmann R, Ehrlich H. Heparin modulates proliferation, protein synthesis, and lattice contraction. Gastroenterology 93: 801-809, 1987.
20. Gisbert JP, Linares PM, McNicholl AG, Mate J, Gomollon F. Metaanalysis: the efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther 30: 126-137, 2009.
21. Hampe J, Franke A, Rosentiel P, Till A, Teuber M, Huse K, Albrecht M, Mayr G, De La Vega FM, Briggs J, Günther S, Prescott NJ, Onnie CM, Häsler R, Sipos B, Fölsch UR, Lengauer T, Platzer M, Mathew CG, Krawczak M, Schreiber S. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet 39: 207-211, 2007.
22. Holm AM, Anderson CB, Haunsø S, Hansen PR. ACE-inhibition promotes apoptosis after balloon injury of rat carotid arteries. Cardiovasc Res 45: 777-782, 2000.
23. Hugot JP, Laurent-Puig P, Gower-Rousseau C, Olson JM, Lee JC, Beaugerie L, Naom I, Dupas JL, Van Gossum A, Orholm M, Bonaiti-Pellie C, Weissenbach J, Mathew CG, Lennard-Jones JE, Cortot A, Colombel JF, Thomas G. Mapping of a susceptibility locus for Crohn's disease on chromosome 16. Nature 379: 821-823, 1996.
24. Ina K, Itoh J, Fukushima K, Kusugami K, Yamaguchi T, Kyokane K, Imada A, Binion DG, Musso A, West GA, Dobrea GM, McCormick TS, Lapetina EG, Levine AD, Ottaway CA, Fiocchi C. Resistance of Crohn's disease T cells to multiple apoptotic signals is associated with a Bcl-2/Bax mucosal imbalance. J Immunol 163: 1081-1090, 1999.
25. Iredale JP, Benyon RC, Pickering J, McCullen M, Northrop M, Pawley S, Hovell C, Arthur MJ. Mechanisms of spontaneous resolution of rat liver fibrosis: hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 102: 538-549, 1998.
26. Issa R, Williams E, Trim N, Kendall T, Arthur MJ, Reichen J, Benyon RC, Iredale JP. Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors. Gut 48: 548-557, 2001.
27. Jaster R, Brock P, Sparmann G, Emmrich J, Liebe S. Inhibition of pancreatic stellate cell activation by the hydroxymethylglutaryl coenzyme A reductase inhibitor lovastatin. Biochem Pharmacol 65: 1295-1303, 2003.
28. Johnson PR, Armour CL, Carey D, Black JL. Heparin and PGE2 inhibit DNA synthesis in human airway smooth muscle cells in culture. Am J Physiol Lung Cell Mol Physiol 269: L514-L519, 1995.
29. Jonsson JR, Clouston AD, Ando Y, Kelemen LI, Horn MJ, Adamson MD, Purdie DM, Powell EE. Angiotensin-converting enzyme inhibition attenuates the progression of rat hepatic fibrosis. Gastroenterology 121: 148-155, 2001.
30. Jordana M, Schulman J, McSharry C, Irving L, Newhouse M, Jordana G, Gauldie J. Heterogeneous proliferative characteristics of human adult lung fibroblast lines and clonally derived fibroblasts from control and fibrotic tissue. Am Rev Respir Dis 137: 579-584, 1988.
31. Klopcic B, Appelbee A, Raye W, Lloyd F, Jooste JCI, Forrest CH, Lawrance IC. Indomethacin and retinoic acid modify inflammationinduced intestinal fibrosis. Dig Dis Sci 53: 1553-1563, 2008.
32. Lawrance IC, Fiocchi C, Chakravarti S. Ulcerative colitis and Crohn's disease: distinctive gene expression profiles and novel susceptibility candidate genes. Hum Mol Genet 10: 445-456, 2001.
33. Lawrance IC, Maxwell L, Doe W. Inflammation location, but not type, determines the increase in TGF-beta1 and IGF-1 expression and collagen deposition in IBD intestine. Inflamm Bowel Dis 7: 16-26, 2001.
34. Li C, Yang CW, Park JH, Lim SW, Sun BK, Jung JY, Kim SB, Kim YS, Kim J, Bang BK. Pravastatin treatment attenuates interstitial inflammation and fibrosis in a rat model of chronic cyclosporine-induced nephropathy. Am J Physiol Renal Physiol 286: F46-F57, 2004.
35. Lieber CS, DeCarli LM, Mak KM, Kim CI, Leo MA. Attenuation of alcohol-induced hepatic fibrosis by polyunsaturated lecithin. Hepatology 12: 1390-1398, 1990.
36. Lieber CS, Robins SJ, Li J, DeCarli LM, Mak KM, Fasulo JM, Leo MA. Phosphatidylcholine protects against fibrosis and cirrhosis in the baboon [see comments]. Gastroenterology 106: 152-159, 1994.
37. Liu WB, Wang XP, Wu K, Zhang RL. Effects of angiotensin II receptor antagonist, Losartan on the apoptosis, proliferation and migration of the human pancreatic stellate cells. Word J Gastroenterol 11: 6489-6494, 2005.
38. Louneva N, Huaman G, Fertala J, Jimenez SA. Inhibition of systemic sclerosis dermal fibroblasts type I collagen production and gene expression by simvastatin. Arthritis Rheum 54: 1298-1308, 2006.
39. Luna J, Masamunt MC, Mora R, España C, Rickmann M, Llach J, Delgado S, Vaquero E, Sans M. Palm oil tocotrienol rich fraction (TRF) reduces extracellular matrix proteins production by counteracting TGFβ1 profibrogenic effects in human intestinal fibroblasts (Abstract). J Crohns Colitis 4: S18, 2010.
40. Luna J, Masamunt MC, Rickmann M, Mora R, España C, Delgado S, Llach J, Vaquero E, Sans M. Tocotrienols have potent antifibrogenic effects in human intestinal fibroblasts. Inflamm Bowel Dis. Epub ahead of print.
41. Masamunt MC, Figueroa C, Angulo SM, Aceituno M, Morales M, Gasull X, Sancho P, Delgado S, Llach J, Panes J, Bataller R, Sans M. Selective proliferative response of inflammatory bowel disease, but not normal human intestinal fibroblasts to angiotensin II (Abstract). Gut 39: S3: A121, 2007.
42. Matsumoto K, Nakamura T. Hepatocyte growth factor: renotropic role and potential therapeutics for renal diseases. Kidney Int 59: 2023-2038, 2001.
43. Mauviel A, Kähäri V, Heino J, Daireaux M, Hartmann D, Loyau G, Pujol J. Gene expression of fibroblast matrix proteins is altered by indomethacin. FEBS Lett 231: 125-129, 1988.
44. McDermott DH, Fong AM, Yang Q, Sechler JM, Cupples LA, Merrell MN, Wilson PW, D'Agostino RB, O'Donnell CJ, Patel DD, Murphy PM. Chemokine receptor mutant CX3CR1-M280 has impaired adhesive function and correlates with protection from cardiovascular disease in humans. J Clin Invest 111: 1241-1250, 2003.
45. Mitoma H, Horiuchi T, Tsukamoto H, Tamimoto Y, Kimoto Y, Uchino A, To K, Harashima S, Hatta N, Harada M. Mechanisms for cytotoxic effects of anti-tumor necrosis factor agents on transmembrane tumor necrosis factor alpha-expressing cells: comparison among infliximab, etanercept, and adalimumab. Arthritis Rheum 58: 1248-1257, 2008.
46. Mizuno S, Matsumoto K, Li MY, Nakamura T. HGF reduces advancing lung fibrosis in mice: a potential role for MMP-dependent myofibroblast apoptosis. FASEB J 19: 580-582, 2005.
47. Moatti D, Faure S, Fumeron F, Amara Mel-W, Seknadji P, McDermott DH, Debré P, Aumont MC, Murphy PM, de Prost D, Combadière C. Polymorphism in the fractalkine receptor CX3CR1 as a genetic risk factor for coronary artery disease. Blood 97: 1925-1928, 2001.
48. Monteleone I, Monteleone G, Fina D, Caruso R, Petruzziello C, Calabrese E, Biancone L, Pallone F. A functional role of flip in conferring resistance of Crohn's disease lamina propria lymphocytes to FAS-mediated apoptosis. Gastroenterology 130: 389-397, 2006.
49. Moreno M, Gonzalo T, Kok RJ, Sancho-Bru P, van Beuge M, Swart J, Prakash J, Temming K, Fondevila C, Beljaars L, Lacombe M, van der Hoeven P, Arroyo V, Poelstra K, Brenner DA, Ginès P, Bataller R. Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats. Hepatology 51: 942-952, 2010.
50. Mourelle M, Guarner F, Malagelada JR. Polyunsaturated phosphatidylcholine prevents stricture formation in a rat model of colitis. Gastroenterology 110: 1093-1097, 1996.
51. Murphy FR, Issa R, Zhou X, Ratnarajah S, Nagase H, Arthur MJ, Benyon C, Iredale JP. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. J Biol Chem 277: 11069-11076, 2002.
52. Neuberger J, Hegarty J, Eddleston A, Williams R. Effect of polyunsaturated phosphatidylcholine on immune mediated hepatocyte damage. Gut 24: 751-755, 1983.
53. Oakley F, Teoh V, Ching-A-Sue G, Bataller R, Colmenero J, Jonsson J, Eliopoulos A, Watson M, Manas D, Mann D. Angiotensin II activates I kappaB kinase phosphorylation of RelA at Ser 536 to promote myofibroblast survival and liver fibrosis. Gastroenterology 136: 2334-2344, 2009.
54. Otte JM, Rosenberg IM, Podolsky DK. Intestinal myofibroblasts in innate immune responses of the intestine. Gastroenterology 124: 1866-1878, 2003.
55. Pacheco S, Hillier K, Smith CL. Inflammatory bowel disease: the in vitro effect of sulphasalazine and other agents on prostaglandin synthesis by human rectal mucosa. Braz J Med Biol Res 20: 221-230, 1987.
56. Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 123: 132-142, 1995.
57. Peppelenbosch MP, van Deventer SJ. T cell apoptosis and inflammatory bowel disease. Gut 53: 1556-1558, 2004.
58. Phan SH. The myofibroblast in pulmonary fibrosis. Chest 122, Suppl 6: 286S-289S, 2002.
59. Prefontaine E, Sutherland LR, Macdonald JK, Cepoiu M. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 1: CD000067, 2009.
60. Qong Q, Davis M, Chipitsyna G, Yeo CJ, Arafat HA. Blocking angiotensin II Type 1 receptor triggers apoptotic cell death in human pancreatic cancer cells. Pancreas 39: 581-594, 2010.
61. Qu X, Zou Z, Sun Q, Luby-Phelps K, Cheng P, Hogan RN, Gilpin C, Levine B. Autophagy gene-dependent clearance of apoptotic cells during embryonic development. Cell 128: 931-946, 2007.
62. Rickmann M, Vaquero EC, Malagelada JR, Molero X. Tocotrienols induce apoptosis and autophagy in rat pancreatic stellate cells through the mitochondrial death pathway. Gastroenterology 132: 2518-2531, 2007.
63. Rioux JD, Xavier RJ, Taylor KD, Silverberg MS, Goyette P, Huett A, Green T, Kuballa P, Barmada MM, Datta LW, Shugart YY, Griffiths AM, Targan SR, Ippoliti AF, Bernard EJ, Mei L, Nicolae DL, Regueiro M, Schumm LP, Steinhart AH, Rotter JI, Duerr RH, Cho JH, Daly MJ, Brant SR. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet 39: 596-604, 2007.
64. Rombouts K, Kisanga E, Hellemans K, Wieland A, Schuppan D, Geerts A. Effect of HMG-CoA reductase inhibitors on proliferation and protein synthesis by rat hepatic stellate cells. J Hepatol 38: 564-572, 2003.
65. Sabate JM, Ameziane N, Lamoril J, Jouet P, Farmachidi JP, Soulé JC, Harnois F, Sobhani I, Jian R, Deybach JC, de Prost D, Coffin B. The V249I polymorphism of the CX3CR1 gene is associated with fibrostenotic disease behavior in patients with Crohn's disease. Eur J Gastroenterol Hepatol 20: 748-755, 2008.
66. Saka M, Obata K, Ichihara S, Cheng XW, Kimata H, Noda A, Izawa H, Nagata K, Yokota M. Attenuation of ventricular hypertrophy and fibrosis in rats by pitavastatin: potential role of the RhoA-extracellular signal-regulated kinase-serum response factor signalling pathway. Clin Exp Pharmacol Physiol 33: 1164-1171, 2006.
67. Sandborn WJ, Hanauer SB, Katz S, Safdi M, Wolf DG, Baerg RD, Tremaine WJ, Johnson T, Diehl NN, Zinsmeister AR. Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 121: 1088-1094, 2001.
68. Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2: CD000545, 2000.
69. Schor A, Rushton G, Ferguson J, Howell A, Redford J, Schor S. Phenotypic heterogeneity in breast fibroblasts: functional anomaly in fibroblasts from histologically normal tissue adjacent to carcinoma. Int J Cancer 59: 25-32, 1994.
70. Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OØ, Hanauer SB, McColm J, Bloomfield R, Sandborn WJ. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 357: 239-250, 2007.
71. Schreiber S, Rutgeerts P, Fedorak RN, Khaliq-Kareemi M, Kamm MA, Boivin M, Bernstein CN, Staun M, Thomsen OØ, Innes A. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 129: 807-818, 2005.
72. Shen C, Assche GV, Colpaert S, Maerten P, Geboes K, Rutgeerts P, Ceuppens JL. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment Pharmacol Ther 21: 251-258, 2005.
73. Sturm A, Leite AZ, Danese S, Krivacic KA, West GA, Mohr S, Jacobberger JW, Fiocchi C. Divergent cell cycle kinetics underlie the distinct functional capacity of mucosal T cells in Crohn's disease and ulcerative colitis. Gut 53: 1624-1631, 2004.
74. Tabata C, Kadokawa Y, Tabata R, Takahashi M, Okoshi K, Saka iY, Mishima M, Kubo H. All-trans-retinoic acid prevents radiation-or bleomycin-induced pulmonary fibrosis. Am J Respir Crit Care Med 174: 1352-1356, 2006.
75. Tan A, Levrey H, Dahm C, Polunovsky VA, Rubins J, Bitterman PB. Lovastatin induces fibroblast apoptosis in vitro and in vivo: a possible therapy for fibroproliferative disorders. Am J Respir Crit Care Med 159: 220-227, 1999.
76. Torry DJ, Richards CD, Podor TJ, Gauldie J. Modulation of the anchorage-independent phenotype of human lung fibroblasts obtained from fibrotic tissue following culture with retinoid and corticosteroid. Exp Lung Res 22: 231-244, 1996.
77. Umeda Y, Marui T, Matsuno Y, Shirahashi K, Iwata H, Takagi H, Matsumoto K, Nakamura T, Kosugi A, Mori Y, Takemura H. Skeletal muscle targeting in vivo electroporation-mediated HGF gene therapy of bleomycin-induced pulmonary fibrosis in mice. Lab Invest 84: 836-844, 2004.
78. Umehara H, Bloom ET, Okazaki T, Nagano Y, Yoshie O, Imai T. Fractalkine in vascular biology: from basic research to clinical disease. Arterioscler Thromb Vasc Biol 24: 34-40, 2004.
79. Wasmuth HE, Zaldivar MM, Berres ML, Werth A, Scholten D, Hillebrandt S, Tacke F, Schmitz P, Dahl E, Wiederholt T, Hellerbrand C, Berg T, Weiskirchen R, Trautwein C, Lammert F. The fractalkine receptor CX3CR1 is involved in liver fibrosis due to chronic hepatitis C infection. J Hepatol 48: 208-215, 2008.
80. Watson MR, Wallace K, Gieling RG, Manas DM, Jaffray E, Hay RT, Mann DA, Oakley F. NF-κB is a critical regulator of the survival of rodent and human hepatic myofibroblasts. J Hepatol 48: 589-597, 2008.
81. Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447: 661-678, 2007.
82. Wengrower D, Zanninelli G, Pappo O, Latella G, Sestieri M, Villanova A, Faitelson Y, Pines M, Goldin E. Prevention of fibrosis in experimental colitis by captopril: the role of tgf-beta1. Inflamm Bowel Dis 10: 536-545, 2004.
83. Wilborn J, Crofford LJ, Burdick MD, Kunkel SL, Strieter RM, Peters Golden M. Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin E2 and to express cyclooxygenase-2. J Clin Invest 95: 1861-1868, 1995.
84. Wright MC, Issa R, Smart DE, Trim N, Murray GI, Primrose JN, Arthur MJ, Iredale JP, Mann DA. Gliotoxin stimulates the apoptosis of human and rat hepatic stellate cells and enhances the resolution of liver fibrosis in rats. Gastroenterology 121: 685-698, 2001.
85. Yaekashiwa M, Nakamura S, Ohnuma K, Sakai T, Abe T, Satoh K, Matsumoto K, Nakamura T, Takahashi T, Nukiwa T. Simultaneous or delayed administration of hepatocyte growth factor equally represses the fibrotic changes in murine lung injury induced by bleomycin: a morphologic study. Am J Respir Crit Care Med 156: 1937-1944, 1997.
86. Yang JI, Yoon JH, Bang YJ, Lee SH, Lee SM, Byun HJ, Myung SJ, Kim W, Lee HS. Synergistic antifibrotic efficacy of statin and protein kinase C inhibitor in hepatic fibrosis. Am J Physiol Gastrointest Liver Physiol 298: G126-G132, 2010.
87. Yoshiji H, Noguchi R, Ikenaka Y, Namisaki T, Kitade M, Kaji K, Shirai Y, Yoshii J, Yanase K, Yamazaki M, Tsujimoto T, Kawaratani H, Akahane T, Aihara Y, Fukui H. Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat. BMC Res Notes 2: 70, 2009.